ReviewEndocrine2025
A practical use of bone turnover markers in management of patients with skeletal fragility.
Review in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Real-world effectiveness of denosumab compared to teriparatide in patients with severe osteoporosis.Frontiers in endocrinology · 2026Article
- Research progress of diabetic osteoporosis: a comprehensive review.Frontiers in endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeBone turnover markers (BTMs) are metabolites produced during the bone remodeling cycle. BTMs can be distinguished in bone formation (procollagen type I N-terminal propeptide, bone-specific alkaline phosphatase and osteocalcin) and bone resorption markers (C-terminal telopeptide of type 1 collagen, N-terminal telopeptide of type 1 collagen and the tartrate-resistant isoform 5b of acid phosphatase). The evaluation of BTMs can offer dynamic information on bone turnover, making it a valuable tool for the management of patients with bone metabolic diseases.
resultsIn the context of osteoporosis, BTMs have demonstrated utility in the monitoring of adherence and response to bone-active treatment, as well as in the management of treatment withdrawal. Additionally, they can be helpful in the evaluation of secondary osteoporosis, mainly when bone turnover is low. However, BTM assessment could be influenced by considerable biological and analytical variability, which must be addressed to ensure a correct clinical interpretation of the values. An accurate patient evaluation is therefore essential for selecting the most reliable biomarker to adopt in clinical practice and appropriate sample handling is critical for minimizing analytical variability.
conclusionsIn recent decades, the applications of BTMs in metabolic bone diseases have expanded significantly and future research will further highlight the role of these markers in the clinical management of osteoporosis.
Indexed as
Identifiers
40439877What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.